Overview

A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients

Status:
RECRUITING
Trial end date:
2029-10-01
Target enrollment:
Participant gender:
Summary
A Feasibility Trial of PVX7 vaccine in advanced cervical cancer patients who have completed primary definitive therapy.
Phase:
PHASE1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborator:
National Institutes of Health (NIH)
Treatments:
human papillomavirus vaccine, TA